Sounds a bit like IBM and Microsoft in the race to develop the first operating system. First to market wins especially so with a superior product and often even with an inferior product.
On this occassion Vascepa + Statin is superior and it is difficult to see AZNs angle on this. It's like a Poker bluff with all their cards showing...or perhaps, if you pardon a mixing of my metaphors, they are behaving like an irrational spurned lover jilted at the altar....hmmmmm
Severe Trig Ad Com...should be concerning since Vascepa got a pass. They'll need safety data with those DHA levels much higher than Lovaza. LDL? & Afib warning?
Epanova gives one the trots pretty good after one has taken it for a while, I think. Why else would they limit the duration of their Anchor study to only 6 weeks. I think the drug may have a tough time receiving widespread durable adoption. Maybe one script and one refill but the burps and fishy runny stuff in the toilet are major turnoffs for long term use. No reason for an omega three to be uptaken into the body that fast... Would you want to be burping up fishy for the rest of your life?
News 
Market Data 
Discover 
